Janine A. Carlan

Partner
Janine Carlan is a patent litigator with more than 20 years of experience.
Janine Carlan, Partner at Arent Fox

Client Work

Recognized as one of the Most Powerful and Influential Women in the region for 2010 by the National Diversity Council, Janine represents clients in bench and jury trials throughout the United States. She has particular expertise in Hatch-Waxman cases, International Trade Commission (ITC) Section 337 cases, and cases defending companies against claims by Non-Practicing Entities. Janine has first-chaired numerous federal district court cases, has argued Federal Circuit appeals, and has been involved in patent cases covering diverse areas of technology including pharmaceuticals, medical devices, electronics, software, Internet content delivery, automotive parts, chemicals, manufacturing processes, furniture, and plastics processing.

Janine represents companies in proceedings before the Patent Trademark and Appeal Board, including filing petitions for IPR.

She was also of counsel before the United States Supreme Court in the case The Holmes Group, Inc. v. Vornado Air Cir. Systems.

Janine serves as Chair of the firm’s Women’s Initiative Committee.

Previous Work

Prior to becoming an attorney, Janine worked as an engineer at FMC Pharmaceuticals, McNeil Consumer Healthcare, and AstraZeneca in the areas of regulatory affairs, research and development, and pharmaceutical manufacturing.

Publications, Presentations & Recognitions

Publications

  • "Bioshield II: The proposed legislation includes controversial provisions for pharmaceutical companies," Pharma & Bio Ingredients
  • "Vioxx: A Painful Decision," Pharma & Bio Ingredients
  • "Two Key Decisions: The Merck and Purdue Cases Could Impact the Work of Every Pharmaceutical Researcher," Pharma & Bio Ingredients
  • "Authorized Generics, Despite a Flurry of Activity, Controversy Continues to Surround the Category," Pharma & Bio Ingredients
  • "IP Protection (in India and China) Intellectual Property Rights and Enforcement has been Troublesome for Decades, but Recent Dramatic Changes have Occurred," Pharma & Bio Ingredients
  • "Hatch-Waxman, A look back after 20 years of regulation and a look ahead to pending provisions," Pharma & Bio Ingredients
  • "New Medicare Law Brings New Considerations for “Paragraph IV Litigation," Food and Drug Law Institute Update

Presentations

  • “Analysis of New Patent Reform Legislation and Its Possible Impact on Post-Grant PTO Proceedings,” American Conference Institute (ACI) Post-Grant PTO Proceedings; New York, NY
  • “Workshop on Overcoming Elicit Bias,” ACI Conference on Women Leaders in Life Sciences Law; Boston, MA
  • “Latest Developments in Pharma/Life Sciences Patent Litigation,” Fordham University School of Law IP Summit
  • “Purpose, Passion, and Performance — A New Era,” The Washington DC, Maryland, and Virginia (DMV) Diversity Council First Annual Women in Leadership Symposium
  • “Litigation and Technology and Intellectual Property Common Interest Agreements: Dangerous Liaisons?” Washington Metropolitan Area Corporate Counsel Association
  • “Litigating with Multiple ANDA Filers: Brand Name and Generic Perspectives,” American Conference Institute (ACI) Conference on Paragraph IV Disputes; San Francisco, CA
  • “Notable Decisions from the ITC,” University of Baltimore conference on the Domestic Impact of Intellectual Property in a Global Economy; Baltimore, MD”Secondary Consideration Experts: The Clinician,” ACI Paragraph IV On Trial, New York, NY”Implications of the Quanta v. LG Case;” Maryland State Bar Association Intellectual Property Association; webinar
  • “Secondary Consideration Experts: The Clinician,” ACI Paragraph IV On Trial, New York, NY
  • “Discovery in Paragraph IV Matters: Documents, Experts and Privilege – A Look from Both Sides,” ACI Conference on Paragraph IV Disputes”
  • Patentability of ‘Reach-Through’ Claims: US, European and Japanese Patent Office Perspectives,” ACI Advanced Forum on Biotech Patents Conference in San Francisco, CA

Recognition

  • National Diversity Council Recognized Janine as one of the Most Powerful and Influential Women of 2010.